Hologic, Inc. (NASDAQ:HOLX) shares gapped down before the market opened on Friday . The stock had previously closed at $41.98, but opened at $38.80. Hologic shares last traded at $37.75, with a volume of 8334832 shares.

Several research analysts have weighed in on HOLX shares. Goldman Sachs Group upgraded shares of Hologic from a “buy” rating to a “conviction-buy” rating and upped their target price for the stock from $45.00 to $50.00 in a research report on Friday, December 8th. Zacks Investment Research lowered shares of Hologic from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th. Cowen upgraded shares of Hologic from a “market perform” rating to an “outperform” rating and set a $51.00 target price on the stock in a research report on Monday, December 11th. Needham & Company LLC restated a “buy” rating and set a $50.00 target price on shares of Hologic in a research report on Friday, November 3rd. Finally, BidaskClub lowered shares of Hologic from a “hold” rating to a “sell” rating in a research report on Saturday, January 13th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $48.36.

The stock has a market cap of $10,438.97, a price-to-earnings ratio of 18.41, a PEG ratio of 1.76 and a beta of 0.77. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.61 and a current ratio of 0.79.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.50 by $0.05. Hologic had a net margin of 34.53% and a return on equity of 20.75%. The company had revenue of $791.10 million for the quarter, compared to the consensus estimate of $785.80 million. During the same quarter in the prior year, the firm earned $0.52 earnings per share. The company’s revenue for the quarter was up 7.7% compared to the same quarter last year. equities analysts expect that Hologic, Inc. will post 2.25 EPS for the current year.

In other Hologic news, Director Elaine Ullian sold 9,282 shares of the company’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $40.50, for a total value of $375,921.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Karleen Marie Oberton sold 1,023 shares of the company’s stock in a transaction dated Monday, November 20th. The shares were sold at an average price of $39.84, for a total transaction of $40,756.32. The disclosure for this sale can be found here. 0.79% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Stanley Laman Group Ltd. lifted its stake in shares of Hologic by 4.7% during the fourth quarter. Stanley Laman Group Ltd. now owns 125,732 shares of the medical equipment provider’s stock valued at $5,375,000 after buying an additional 5,639 shares during the period. Ontario Teachers Pension Plan Board lifted its stake in shares of Hologic by 12.6% during the fourth quarter. Ontario Teachers Pension Plan Board now owns 69,990 shares of the medical equipment provider’s stock valued at $2,992,000 after buying an additional 7,811 shares during the period. American International Group Inc. lifted its stake in shares of Hologic by 8.0% during the fourth quarter. American International Group Inc. now owns 107,449 shares of the medical equipment provider’s stock valued at $4,593,000 after buying an additional 7,982 shares during the period. TCW Group Inc. purchased a new position in shares of Hologic during the fourth quarter valued at approximately $547,000. Finally, Homrich & Berg purchased a new position in shares of Hologic during the fourth quarter valued at approximately $219,000. 92.77% of the stock is currently owned by institutional investors.

WARNING: “Hologic (HOLX) Shares Gap Down to $38.80” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.thecerbatgem.com/2018/02/11/hologic-holx-shares-gap-down-to-38-80.html.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.